Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis

Inclusion Criteria: 1. Patients with confirmed invasive candidiasis or confirmed/probable/possible invasive aspergillosis; 2. Agree to use contraceptive measures from the date of signing the informed consent to 6 weeks after the end of the last medication; 3. Female subjects must meet one of the following conditions: surgical sterilization;menopause for at least 1 year;a negative result of serum/urine pregnancy test before enrollment. 4. Signed Informed Consent Form. Exclusion Criteria: 1. Allergic to ABCD or azole antifungal drugs； 2. For IC patients, administration of more than 48 hours of systemic antifungal treatment within 96 hours before enrollment; or 1 dose of amphotericin B in 7 days; 3. For IA patients, administration of more than 96 hours of systemic antifungal therapy for this infection before enrollment, or 1 dose of amphotericin B in 7 days; 4. Patients with Candida endocarditis, osteomyelitis, arthritis, endophthalmitis, abscess of liver and/or spleen, suppurative thrombophlebitis, or central nervous system infection; 5. Patients with a history of drug abuse or drug dependence; 6. Chronic pulmonary aspergillosis (duration ≥ 3 months), aspergilloma or allergic bronchopulmonary aspergillosis; 7. Patients are known to have mixed invasive Candida or Aspergillus infections and/or ABCD is known to be ineffective; 8. Patients with abnormal liver function; 9. Patients with reduced renal function who require or are currently undergoing hemodialysis or peritoneal dialysis; 10. Hypokalemia, which cannot be corrected before trial treatment; 11. Expected survival time is less than 2 months; 12. Patients with cardiac function of New York Heart Association（NYHA）class III/IV; 13. Positive for HIV antibody; 14. Pregnant or lactating women;